| Antiangiogenic therapy for cancer: an update B Al‐Husein, M Abdalla, M Trepte, DL DeRemer, PR Somanath Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32 (12 …, 2012 | 247 | 2012 |
| Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia DL DeRemer, C Ustun, K Natarajan Clinical therapeutics 30 (11), 1956-1975, 2008 | 230 | 2008 |
| Tyrosine kinase inhibitors in the treatment of systemic mastocytosis C Ustun, DL DeRemer, C Akin Leukemia research 35 (9), 1143-1152, 2011 | 153 | 2011 |
| Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma … M Hamadani, ST Kochuparambil, S Osman, A Cumpston, S Leadmon, ... Biology of blood and marrow transplantation 18 (7), 1128-1135, 2012 | 97 | 2012 |
| Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo A Goc, B Al-Husein, K Katsanevas, A Steinbach, U Lou, H Sabbineni, ... Oncotarget 5 (3), 775, 2014 | 77 | 2014 |
| Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence LM Willis, AB El-Remessy, PR Somanath, DL Deremer, SC Fagan Clinical Science 120 (8), 307-319, 2011 | 77 | 2011 |
| The importance of research and scholarly activity in pharmacy training EN Deal, PM Stranges, WD Maxwell, J Bacci, EJ Ashjian, DL DeRemer, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36 (12 …, 2016 | 63 | 2016 |
| Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma … F Awan, ST Kochuparambil, DE Falconer, A Cumpston, S Leadmon, ... Bone marrow transplantation 48 (10), 1279-1284, 2013 | 58 | 2013 |
| Brentuximab vedotin: an anti-CD30 antibody–drug conjugate AM Bradley, M Devine, D DeRemer American Journal of Health-System Pharmacy 70 (7), 589-597, 2013 | 52 | 2013 |
| Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy … AB Clemmons, J Orr, B Andrick, A Gandhi, C Sportes, D DeRemer Biology of Blood and Marrow Transplantation 24 (10), 2065-2071, 2018 | 48 | 2018 |
| Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. B Andrick, A Alwhaibi, DL DeRemer, S Quershi, R Khan, LJ Bryan, ... British journal of haematology 182 (5), 712-714, 2017 | 47 | 2017 |
| Pharmacy student performance in a capstone course utilizing the pharmacists’ patient care process BB Phillips, AS Newsome, CM Bland, R Palmer, K Smith, DL DeRemer, ... American journal of pharmaceutical education 83 (8), 7357, 2019 | 37 | 2019 |
| How to Transition from Single Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial CDHRM Marrero RJ, Cicali EJ, Arwood MJ, Eddy E, DeRemer D, Ramnaraign BH ... Clin Pharmacol Ther 108 (3), 557-565, 2020 | 26 | 2020 |
| Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors ME Gwynn, DL DeRemer, KM Saunders, J Parikh, RJ Bollag, ... Journal of Oncology Pharmacy Practice 26 (3), 647-654, 2020 | 23 | 2020 |
| Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center N Waheed, MG Fradley, DL DeRemer, A Mahmoud, CP Shah, ... Cardio-oncology 7, 1-7, 2021 | 22 | 2021 |
| Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients ME Hartranft, AB Clemmons, DL DeRemer, V Kota Journal of Oncology Pharmacy Practice 23 (1), 10-17, 2017 | 21 | 2017 |
| Emerging role of olanzapine for prevention and treatment of chemotherapy‐induced nausea and vomiting DL DeRemer, AB Clemmons, J Orr, SM Clark, AS Gandhi Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36 (2 …, 2016 | 21 | 2016 |
| National survey on the effect of oncology drug shortages in clinical practice: a hematology oncology pharmacy association survey A McBride, S Hudson-DiSalle, J Pilz, M Hamm, B Boring, LW Buie, ... JCO oncology practice 18 (8), e1289-e1296, 2022 | 19 | 2022 |
| Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood progenitor cell mobilization FT Awan, ST Kochuparambil, D DeRemer, A Cumpston, M Craig, A Jillella, ... Journal of Oncology 2012, 2012 | 18 | 2012 |
| Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis G Lewis, P Hall, N Eisa, D Deremer, R Dobbins, M El-Geneidy, A Jillella, ... Acta haematologica 124 (4), 206-213, 2010 | 17 | 2010 |
Somanath P. R. ShenoyUniversity of GeorgiaVerified email at uga.edu
